Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06593210 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

RSV Vaccine in Transplant Recipients

Study acronym: RSVax
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 1, 2026 (before its estimated September 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Recruiting to Active, Not Recruiting Primary and study completion dates: Mar 2026 to Sep 2026 · Site details revised · Collaborators revised (2)v6 Show 3 more changesShow less
    • Primary and study completion dates: Mar 2026 to Sep 2026
    • Site details revised
    • Collaborators revised (2)

    See this version in full on ClinicalTrials.gov ↗

  2. Primary completion date: Oct 2025 to Mar 2026 Completion date: Feb 2026 to Mar 2026v5 Show 1 more changeShow less
    • Completion date: Feb 2026 to Mar 2026
  3. Completion date: Dec 2025 to Feb 2026 Secondary endpoints: 3 to 4 · Collaborators expanded, about 8 words · Study description expanded, about 5 wordsv4 Show 3 more changesShow less
    • Secondary endpoints: 3 to 4
    • Collaborators expanded, about 8 words
    • Study description expanded, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  4. Start date changed from estimate of Oct 2024 to Oct 1, 2024v3
  5. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Eligibility criteria expanded, about 86 wordsv2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Eligibility criteria expanded, about 86 words

    See this version in full on ClinicalTrials.gov ↗

  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Adjuvant, non-live RSV vaccine will be administered to adult lung and allogeneic hematopoietic stem cell transplant recipients. The safety and immunogenicity of this intervention will be studied. Blood work will be collected before and after the intervention, to assess humoral and cellular immunity. Participants will be followed for adverse reaction, hospitalization, RSV breakthrough infection, graft rejection or graft versus host disease. This study has Health Canada and UHN REB approval.
Trial Details
NCT Number NCT06593210
Lead Sponsor University Health Network, Toronto
Collaborators: University of British Columbia, The Physicians' Services Incorporated Foundation
Conditions Vaccine Response Impaired, Respiratory Syncytial Virus Infections, Immune Suppression
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov